Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.

ABSTRACT: Despite the initial effectiveness of oncogene-directed cancer therapeutics, acquired drug resistance remains the ultimate "Achilles' heel" for long-term durable remission in cancer patients. Acquisition of drug resistance is not more evident elsewhere than in the use of tyrosine kinase inhibitors, imatinib and dasatinib, for patients with chronic myelogenous leukemia. Hence, even though imatinib initially produces remission in the chronic phase, ultimately these therapeutics fail via the emergence of drug resistance, in which chronic myelogenous leukemia could inevitably progress to a terminal blast phase culminating in fatal outcome. Technically, it is challenging to predict the onset of drug resistance in a small number of oncogene-transformed cells, making the decision of when and how t

SUBMITTER: Tunceroglu A 

PROVIDER: S-EPMC3318989 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature